Parallel Advisors’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-5
| Closed | – | – | 3748 |
|
|
2025
Q1 | $0 | Hold |
5
| – | – | ﹤0.01% | 3726 |
|
|
2024
Q4 | $0 | Hold |
5
| – | – | ﹤0.01% | 3659 |
|
|
2024
Q3 | $0 | Hold |
5
| – | – | ﹤0.01% | 3520 |
|
|
2024
Q2 | $0 | Hold |
5
| – | – | ﹤0.01% | 3477 |
|
|
2024
Q1 | $0 | Hold |
5
| – | – | ﹤0.01% | 3473 |
|
|
2023
Q4 | $0 | Hold |
5
| – | – | ﹤0.01% | 3534 |
|
|
2023
Q3 | $0 | Sell |
5
-21
| -81% | -$828 | ﹤0.01% | 3531 |
|
|
2023
Q2 | $807 | Sell |
26
-31
| -54% | -$796 | ﹤0.01% | 2984 |
|
|
2023
Q1 | $1.2K | Buy |
57
+17
| +43% | +$405 | ﹤0.01% | 2915 |
|
|
2022
Q4 | $917 | Hold |
40
| – | – | ﹤0.01% | 2919 |
|
|
2022
Q3 | $1K | Buy |
40
+14
| +54% | +$281 | ﹤0.01% | 3083 |
|
|
2022
Q2 | $0 | Buy |
26
+21
| +420% | +$330 | ﹤0.01% | 3469 |
|
|
2022
Q1 | $0 | Hold |
5
| – | – | ﹤0.01% | 3379 |
|
|
2021
Q4 | $0 | Hold |
5
| – | – | ﹤0.01% | 3380 |
|
|
2021
Q3 | $0 | Hold |
5
| – | – | ﹤0.01% | 3340 |
|
|
2021
Q2 | $0 | Hold |
5
| – | – | ﹤0.01% | 3106 |
|
|
2021
Q1 | $0 | Hold |
5
| – | – | ﹤0.01% | 2936 |
|
|
2020
Q4 | $0 | Hold |
5
| – | – | ﹤0.01% | 2772 |
|
|
2020
Q3 | $0 | Hold |
5
| – | – | ﹤0.01% | 2719 |
|
|
2020
Q2 | $0 | Hold |
5
| – | – | ﹤0.01% | 2780 |
|
|
2020
Q1 | $0 | Hold |
5
| – | – | ﹤0.01% | 2731 |
|
|
2019
Q4 | $0 | Hold |
5
| – | – | ﹤0.01% | 2530 |
|
|
2019
Q3 | $0 | Hold |
5
| – | – | ﹤0.01% | 2536 |
|
|
2019
Q2 | $0 | Buy |
+5
| New | +$76 | ﹤0.01% | 2474 |
|
Parallel Advisors's KDNY Position: Q2 2025 in Review
Parallel Advisors sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2025, closing a stake of 5 shares.
Parallel Advisors first reported a position in KDNY in Q2 2019 and held it in 24 quarters. The position peaked at $1.2K in Q1 2023. 0 funds tracked by Wall St. Rank hold KDNY as of Q2 2025.
- Parallel Advisors reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2025 after selling out during the quarter.
- Parallel Advisors sold 5 Chinook Therapeutics, Inc. Common Stock shares in Q2 2025.
- Parallel Advisors first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2019 and held it in 24 quarters.
- Parallel Advisors's Chinook Therapeutics, Inc. Common Stock position peaked at $1.2K in Q1 2023.
- 0 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2025.
Based on Parallel Advisors's 13F filing for Q2 2025, filed 8 Jul 2025.